Skip to main content
PROFARMA DISTRIB PROD FARMACEUTICOS S.A. logo

PROFARMA DISTRIB PROD FARMACEUTICOS S.A. — Investor Relations & Filings

ISIN · BRPFRMACNOR1 LEI · 549300P8A8G5XSTA2315 SA Wholesale and retail trade
Open in API
Filings indexed 239 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country BR Brazil
Listing SA

About PROFARMA DISTRIB PROD FARMACEUTICOS S.A.

https://www.profarma.com.br/

Profarma Distribuidora de Produtos Farmacêuticos S.A. specializes in the wholesale distribution and retail of pharmaceutical, personal care, and beauty products. Founded in 1961, the company maintains an extensive logistics infrastructure that connects manufacturers to a network of over 49,000 customers, including pharmacies and healthcare providers across 17 states. Its operations are divided into distribution and retail segments, with the latter comprising brands such as Drogasmil, Farmalife, and Drogarias Tamoio. The company also operates Profarma Specialty, a joint venture dedicated to the distribution of high-complexity medications and specialized health services. By integrating wholesale logistics with retail management, the organization facilitates the supply of medicines, hygiene products, and wellness items, focusing on operational excellence and supply chain efficiency.

Recent filings

Filing Released Lang Actions
FRE - Formulário de Referência
Regulatory Filings
2026-05-11 Portuguese
-
Environmental & Social Information Classification · 95% confidence The document is titled 'Relato Integrado 2025' which translates to 'Integrated Report 2025'. It includes detailed sections on ESG (Environmental, Social, Governance) strategy, financial performance, business model, and sustainability indicators. The text mentions integration of financial and non-financial indicators, assurance aligned with financial statements, and references to international reporting standards such as IIRC, GRI, and SASB. The document covers the full fiscal year 2025 and includes comprehensive information on the company's strategy, governance, social and environmental performance, and financial results. This matches the characteristics of an Environmental & Social Information report, which details the company's ESG performance and sustainability efforts. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or summary. Therefore, the most appropriate classification is Environmental & Social Information (SR).
2026-05-05 Portuguese
Conclusão da aquisição da 4Bio Medicamentos S.A.
Capital/Financing Update Classification · 95% confidence The document is a market communication from Profarma Distribuidora de Produtos Farmacêuticos S.A. announcing the completion of the acquisition of 4Bio Medicamentos S.A. It references compliance with Brazilian Corporations Law and CVM regulations, mentions the approval by an Extraordinary General Meeting and CADE clearance, and provides strategic context and financial highlights of the acquired company. The document is a formal announcement of a corporate transaction (acquisition) rather than a full financial report, earnings release, or regulatory filing. It does not contain detailed financial statements or management discussion but focuses on the acquisition event. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including acquisitions.
2026-05-04 Portuguese
Pagamento de juros/remuneração
Interest Rate Update/Notice Classification · 88% confidence The document is a short market notice (“COMUNICADO A MERCADO”) notifying debenture holders of the upcoming payment of remuneration (coupon) on the company’s 2nd issuance of debentures. This is an interest payment notice on debt instruments rather than a full financial report, dividend on shares, or a capital-raising announcement. It best fits the Interest Rate Update/Notice category (IRAT).
2026-04-27 Portuguese
Anúncio de encerramento da oferta pública de distribuição da 1ª emissão de Notas Comerciais.
Capital/Financing Update Classification · 88% confidence The document is an official announcement (“Anúncio de Encerramento”) of the closing/results of a public distribution of commercial notes (debt issuance) by Profarma. It details the final distribution data, ISIN, issuance amount, regulatory registration and confirms the offering has been concluded. This is a financing activity update (debt issuance), not a full annual/interim report, not an earnings release, and not a simple publication announcement. It fits the Capital/Financing Update category.
2026-04-06 Portuguese
DFP 2025 v2
Regulatory Filings
2026-03-27 Portuguese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.